
    
      SER-262-001 is a Phase 1b, randomized, double blind, placebo-controlled, ascending single
      dose clinical study with 2 treatment arms (SER-262 or placebo) in up to 8 dose cohorts.
      Patients who have been diagnosed with their first (primary) episode of CDI, defined as
      diarrhea (â‰¥ 3 unformed stools per day for 2 consecutive days), a positive C. difficile stool
      test and who have responded to standard-of-care antibiotic will receive investigational drug
      or placebo on Day 1.
    
  